News

Banu K. Arun, MD, discussed the challenge of treating patients with triple-negative breast cancer, the value of genotyping, and what she hopes to see in future trial results.

A new tool could change the surgical landscape of ovarian cancer treatment.

CURE Media Group’s flagship product, CURE® magazine, the nation’s leading consumer digital and print media enterprise focused on patients with cancer, will host its monthly Tweet Chat on Thursday, September 27, at 1 p.m. EDT, for readers to ask questions and to facilitate discussions about women’s cancers.

The FDA has approved the CD22-directed recombinant immunotoxin moxetumomab pasudotox (Lumoxiti) for the treatment of adult patients with relapsed or refractory hairy cell leukemia (HCL) who have received at least 2 prior lines of therapy, including treatment with a purine nucleoside analog.

A study evaluating the implementation of a multifaceted approach to bedside handoffs incorporating the teach-back method and discharge bundles on an inpatient oncology unit at a large military treatment facility showed that patient education reduced patient readmission rate.

The Food and Drug Administration (FDA) granted priority review to pembrolizumab (Keytruda) monotherapy for the first-line treatment of patients with locally advanced or metastatic nonsquamous or squamous non-small cell lung cancer (NSCLC) whose tumors express PD-L1 without EGFR or ALK genomic tumor aberrations.

Researchers conducted a study to determine if virtual reality is effective in reducing anxiety and pain prior to and during a bone marrow aspiration and biopsy.

Ad to ask people to share how they are more than a patient on social media

The FDA granted breakthrough therapy designation to the oral agent LOXO-292 for the treatment of RET fusion–positive non–small cell lung cancer (NSCLC) or RET-mutant medullary thyroid cancer (MTC).

The Food and Drug Administration (FDA) granted priority review to pembrolizumab (Keytruda) for the treatment of adults and children with recurrent locally advanced or metastatic Merkel cell carcinoma, a rare skin cancer.

The FDA launched a pilot program designed to advance innovative clinical trial designs.

As the cost of cancer therapies continues to increase, the cancer community is looking to biosimilars as a potential alternative for treatment; however, experts wonder if factors besides cost need to be taken in to consideration.

New guidelines issued by the US Preventive Services Task Force (USPSTF) recommend for women aged 30 to 65 years at average risk for cervical cancer to choose to receive a Pap smear alone every 3 years, screening with the high-risk human papillomavirus test alone, or cotesting every 5 years.

This year, the Foundation for Women’s Cancer (FWC) is collaborating with SHARE Cancer Support, National Ovarian Cancer Coalition (NOCC) and Tell Every Amazing Lady (T.E.A.L.®) on a national social media campaign featuring the voices of real people.

The Foundation for Women’s Cancer Continues the Fight to end gynecologic cancer one step at a time; race set for Nov. 4, 2018 in Washington, DC.

The Bonnie J. Addario Lung Cancer Foundation (ALCF) and the EGFR Resisters, a patient-driven community of people living with epidermal growth factor receptor (EGFR) positive lung cancer and their loved ones, are working together to raise funds and increase awareness of projects that benefit the EGFR community.

The trial that led to national screening guidelines—which recommend screening based on age and smoking history—did not include fair representation from all racial/ethnic groups.

A recent survey of physicians revealed that 17% of doctors with personal experience with cancer were more likely than those without to act against established guidelines to recommend that low-risk women receive ovarian cancer screening.

Broad-based genomic sequencing, while useful in identifying tumor mutations in patients with non-small cell lung cancer (NSCLC), may not improve survival outcomes when compared to routine genomic testing.

While patients may feel a sense of urgency in making a treatment decision, it’s important for patients to assess their own feelings about their goals for treatment.

Attempting to learn and process large amounts of complex information after a diagnosis of pancreatic cancer can leave anyone feeling lost. So where should you turn? Start with Patient Central.

Getting organized can help patients and their loved ones take control and better understand their options after a cancer diagnosis.

Adverse events (AEs) associated with brentuximab vedotin (BV; Adcetris) - used to treat hematological malignancies - may be serious, and nurses need to understand what they are, monitor for them, and treat them promptly.

Hundreds of oncology professionals will gather in Phoenix, Arizona, to share best practices and creative approaches that address the most pressing issues facing cancer programs in communities around the country.

The FDA has approved the kinase inhibitor ibrutinib (Imbruvica) for use in combination with rituximab (Rituxan) for the treatment of patients with Waldenström macroglobulinemia, a form of non-Hodgkin lymphoma.

Patients who report higher satisfaction with their physicians’ communication with them also were more likely to receive more efficient care with fewer office visits and better health outcomes at lower costs.

African-American and Caucasian patients with metastatic castration-resistant prostate cancer (mCRPC) demonstrated similar overall survival (OS) rates, according to study results presented at the 2018 ASCO Annual Meeting.

The FDA has granted a priority review to the immunostimulatory monoclonal antibody elotuzumab (Empliciti) for use in combination with pomalidomide (Pomalyst) and low-dose dexamethasone (EPd) to treat patients with relapsed/refractory multiple myeloma (MM) who have received 2 or more prior therapies, including lenalidomide (Revlimid) and a proteasome inhibitor.